238 related articles for article (PubMed ID: 18397980)
1. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults.
van der Klaauw AA; van der Straaten T; Baak-Pablo R; Biermasz NR; Guchelaar HJ; Pereira AM; Smit JW; Romijn JA
J Clin Endocrinol Metab; 2008 Jul; 93(7):2828-34. PubMed ID: 18397980
[TBL] [Abstract][Full Text] [Related]
2. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
Giavoli C; Ferrante E; Profka E; Olgiati L; Bergamaschi S; Ronchi CL; Verrua E; Filopanti M; Passeri E; Montefusco L; Lania AG; Corbetta S; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
Eur J Endocrinol; 2010 Sep; 163(3):361-8. PubMed ID: 20592127
[TBL] [Abstract][Full Text] [Related]
3. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
4. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism.
Bianchi A; Giampietro A; Tartaglione L; Chiloiro S; Gentilella R; Bima C; Anile C; Olivi A; Pontecorvi A; De Marinis L
J Neuroendocrinol; 2019 Apr; 31(4):e12692. PubMed ID: 30712287
[TBL] [Abstract][Full Text] [Related]
6. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy.
Claessen KM; Appelman-Dijkstra NM; Adoptie DM; Roelfsema F; Smit JW; Biermasz NR; Pereira AM
J Clin Endocrinol Metab; 2013 Jan; 98(1):352-61. PubMed ID: 23162104
[TBL] [Abstract][Full Text] [Related]
7. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults.
Moyes VJ; Walker DM; Owusu-Antwi S; Maher KT; Metherell L; Akker SA; Monson JP; Clark AJ; Drake WM
Clin Endocrinol (Oxf); 2010 Jun; 72(6):807-13. PubMed ID: 20039885
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
9. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
Adetunji OR; MacFarlane IA; Javadpour M; Alfirevic A; Pirmohamed M; Blair JC
Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543
[TBL] [Abstract][Full Text] [Related]
10. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients.
Mormando M; Chiloiro S; Bianchi A; Giampietro A; Angelini F; Tartaglione L; Nasto L; Milardi D; Formenti AM; Giustina A; De Marinis L
Clin Endocrinol (Oxf); 2016 Nov; 85(5):717-724. PubMed ID: 27437620
[TBL] [Abstract][Full Text] [Related]
12. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
13. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
14. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study.
Appelman-Dijkstra NM; Claessen KM; Hamdy NA; Pereira AM; Biermasz NR
Clin Endocrinol (Oxf); 2014 Nov; 81(5):727-35. PubMed ID: 24816144
[TBL] [Abstract][Full Text] [Related]
15. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
16. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.
Span JP; Pieters GF; Sweep CG; Hermus AR; Smals AG
J Clin Endocrinol Metab; 2000 Mar; 85(3):1121-5. PubMed ID: 10720049
[TBL] [Abstract][Full Text] [Related]
17. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
18. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
19. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency.
van der Klaauw AA; Romijn JA; Biermasz NR; Smit JW; van Doorn J; Dekkers OM; Roelfsema F; Pereira AM
Eur J Endocrinol; 2006 Nov; 155(5):701-8. PubMed ID: 17062886
[TBL] [Abstract][Full Text] [Related]
20. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]